COPD management costs according to the frequency of COPD exacerbations in UK primary care

International Journal of COPD

Volumn 9, Issue , 2014, Pages 65-73

  Punekar, Yogesh Suresh ^a   Shukla, Amit ^b   Müllerova, Hana ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Chronic obstructive pulmonary disease; Frequent exacerbations; Health care costs; Health resources; Infrequent exacerbations

Indexed keywords

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONSULTATION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; GENERAL PRACTITIONER; GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH COUNCIL DYSPNEA SCALE; NATIONAL HEALTH SERVICE; OUTCOME ASSESSMENT; PRIMARY MEDICAL CARE; RATING SCALE; RETROSPECTIVE STUDY; SMOKING; SPIROMETRY; UNITED KINGDOM;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; FREQUENT EXACERBATIONS; HEALTH CARE COSTS; HEALTH RESOURCES; INFREQUENT EXACERBATIONS;

AGED; AGED, 80 AND OVER; COST SAVINGS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; GENERAL PRACTICE; GREAT BRITAIN; HEALTH CARE COSTS; HOSPITAL COSTS; HUMANS; MALE; MIDDLE AGED; OFFICE VISITS; PREVALENCE; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; STATE MEDICINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84892377852     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S54417     Document Type: Article

References (30)

1. Buist AS, McBurnie MA, Vollmer WM, et al; BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007; 370(9589): 741-750.
2. Effing T, Kerstjens H, van der Valk P, Zielhuis G, van der Palen J. (Cost)-effectiveness of self-treatment of exacerbations on the severity of exacerbations in patients with COPD: the COPE II study. Thorax. 2009; 64(11): 956-962.
3. Nurmatov U, Buckingham S, Kendall M, et al. Effectiveness of holistic interventions for people with severe chronic obstructive pulmonary disease: systematic review of controlled clinical trials. PLoS One. 2012; 7(10): e46433.
4. Chetty M, MacKenzie M, Douglas G, Currie GP. Immediate and early discharge for patients with exacerbations of chronic obstructive pulmonary disease: is there a role in "real life"? Int J Chron Obstruct Pulmon Dis. 2006; 1(4): 401-407.
5. Jahnz-Rozyk K, Targowski T, From S. Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007-results of multicenter Polish study. Pol Merkur Lekarski. 2009; 26(153): 208-214. Polish.
6. Nielsen R, Johannessen A, Benediktsdottir B, et al. Present and future costs of COPD in Iceland and Norway: results from the BOLD study. Eur Respir J. 2009; 34(4): 850-857.
7. Ornek T, Tor M, Altin R, et al. Clinical factors affecting the direct cost of patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. Int J Med Sci. 2012; 9(4): 285-290.
8. McGuire A, Irwin DE, Fenn P, et al. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales. Value Health. 2001; 4(5): 370-375.
9. Pasquale MK, Sun SX, Song F, Hartnett HJ, Stemkowski SA. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 2012; 7: 757-764.
10. Dalal AA, Christensen L, Liu F, Riedel AA. Direct costs of chronic obstructive pulmonary disease among managed care patients. Int J Chron Obstruct Pulmon Dis. 2010; 5: 341-349.
11. Miravitlles M, Murio C, Guerrero T, Gisbert R. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest. 2002; 121(5): 1449-1455.
12. Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. BMJ. 1959; 2(5147): 257-266.
13. Mullerova H, Lu C, Tabberer M. Disease burden of dyspnea in a primary care COPD population. Am J Respir Crit Care Med. 2012; 185: A1518.
14. Clinical Practice Research Datalink. Available from: http://www. cprd. com/home/. Accessed October 4, 2012.
15. Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S. Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary. Am J Respir Crit Care Med. 2011; 183(3): 323-329.
16. Gov. UK. Policy paper. NHS reference costs 2010-2011. Available from: https://www. gov. uk/government/publications/2010-11-reference-costs-publication. Accessed October 4, 2012.
17. Buckingham RJ, Lowe D, Pursey NA, Roberts CM, Stone RA. Report of the National Chronic Obstructive Pulmonary Disease Audit 2008: clinical audit of COPD exacerbations admitted to acute NHS units across the UK: Royal College of Physicians, British Thoracic Scoiety, British Lung Foundation, 2008. Available from: http://www. brit-thoracic. org. uk/Portals/0/Clinical%20Information/COPD/NCROP/NCROPClinicalAudit. pdf. Accessed November 17, 2013.
18. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD (2010). Available from: http://www. goldcopd. org/uploads/users/files/GOLDReport_April112011. pdf. Accessed November 17, 2012.
19. Personal Social Services Research Unit. Unit Costs of Health and Social Care 2011. Available from: http://www. pssru. ac. uk/project-pages/unit-costs/2011/index. php. Accessed October 4, 2012.
20. British National Formulary 65, 2012. Available from: http://bnf. org/bnf/index. htm. Accessed October 4, 2012.
21. Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S, Jameson K. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. Int J Chron Obstruct Pulmon Dis. 2012; 7: 183-199.
22. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2006). Available from: http://www. goldcopd. org/uploads/users/files/GOLDReport2006_0122. pdf. Accessed October 4, 2012.
23. National Institute for Health and Care Excellence. Medical Research Council dyspnea scale. Available from: http://www. nice. org. uk/usingguidance/commissioningguides/pulmonaryrehabilitationserviceforpatientswithcopd/mrc_dyspnoea_scale. jsp. Accessed June 20, 2011.
24. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363(12): 1128-1138.
25. Wouters EF. Economic analysis of the Confronting COPD survey: an overview of results. Respir Med. 2003; 97 Suppl C: S3-S14.
26. Schermer TR, Saris CG, van den Bosch WJ, et al. Exacerbations and associated health care cost in patients with COPD in general practice. Monaldi Arch Chest Dis. 2006; 65(3): 133-140.
27. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J. 1995; 8(8): 1398-1420.
28. Andersson F, Borg S, Jansson SA, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med. 2002; 96(9): 700-708.
29. Tabberer M, Lu C, Müllerova H. Incremental burden of dyspnea in COPD to a primary care COPD population. Presented at the Annual Congress of the American Thoracic Society, San Francisco, CA, USA, May 18-23, 2012.
30. Strong M, South G, Carlisle R. The UK Quality and Outcomes Framework pay-for-performance scheme and spirometry: rewarding quality or just quantity? A cross-sectional study in Rotherham, UK. BMC Health Serv Res. 2009; 9: 108.